Allogene Therapeutics, Inc. 10-Q

Item 1. Financial Statements ALLOGENE THERAPEUTICS, INC. Condensed Balance Sheets (Unaudited) (In thousands, except share and per share amounts) March 31, 2026 December 31, 2025 Assets Current assets: Cash and cash equivalents $ 30,309 $ 51,688 Short-term investments 236,577 198,522 Prepaid expenses and other current assets 6,407 7,539 Total current assets 273,293 257,749 Long-term investments — 8,043 Operating lease right-of-use asset 38,819 39,888 Property and equipment, net 70,023 72,839 Deposit placed in escrow — 23,479 Restricted cash 10,292 10,292 Other long-term assets 3,531 3,615 Total assets $ 395,958 $ 415,905 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 4,933 $ 4,270 Accrued and other current liabilities 23,397 28,244 Total current liabilities 28,330 32,514 Lease liability, noncurrent 72,633 75,045 Other long-term liabilities 16,120 15,804 Total liabilities 117,083 123,363 Commitments and Contingencies (Notes 6 and 7) Stockholders’ equity: Preferred stock, $ 0.001 par value: 10,000,000 shares authorized as of March 31, 2026 and December 31, 2025; no shares were issued and outstanding as of March 31, 2026 and December 31, 2025 — — Common stock, $ 0.001 par value: 400,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 244,816,413 and 229,413,523 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively 245 229 Additional paid-in capital 2,332,129 2,302,753 Accumulated deficit ( 2,053,316 ) ( 2,010,709 ) Accumulated other comprehensive income (loss) ( 183 ) 269 Total stockholders’ equity 278,875 292,542 Total liabilities and stockholders’ equity $ 395,958 $ 415,905 The accompanying notes are an integral part of these unaudited condensed financial statements. 1 Table of Contents ALLOGENE THERAPEUTICS, INC. Condensed Statements of Operations and Comprehensive Loss (Unaudited) (In thousands, except share and per share amounts) Three Months Ended March 31, 2026 2025 Operating expenses: Research and development $ 32,003 $ 50,200 General and administrative 14,089 14,991 Total operating expenses 46,092 65,191 Loss from operations ( 46,092 ) ( 65,191 ) Other income (expenses), net: Interest and other income, net 3,573 5,516 Interest expense ( 300 ) ( 150 ) Other income (expenses), net 212 92 Total other income (expenses), net 3,485 5,458 Net loss ( 42,607 ) ( 59,733 ) Other comprehensive income (loss): Net unrealized gain (loss) on available-for-sale investments ( 452 ) 132 Net comprehensive loss $ ( 43,059 ) $ ( 59,601 ) Net loss per share, basic and diluted $ ( 0.18 ) $ ( 0.28 ) Weighted-average number of shares used in computing net loss per share, basic and diluted 240,290,782 215,358,619 The accompanying notes are an integral part of these unaudited condensed financial statements. 2 Table of Contents ALLOGENE THERAPEUTICS, INC. Condensed Statements of Stockholders’ Equity (Unaudited) (In thousands, except share amounts) Common Stock Additional Paid-in Capital Accumulated Deficit Accumulated Other Comprehensive Income (Loss) Total Stockholders’ Equity Shares Amount Balance - December 31, 2025 229,413,523 $ 229 $ 2,302,753 $ ( 2,010,709 ) $ 269 $ 292,542 Issuance of common stock upon exercise of stock options and vesting of RSUs 2,476,547 2 2 — — 4 Issuance of common stock from ATM offering, net of commissions and offering costs of $ 0.3 million 12,476,533 13 20,655 — — 20,668 Stock-based compensation — 8,270 — — 8,270 Employee stock purchase plan 449,810 1 449 — — 450 Net loss — — — ( 42,607 ) — ( 42,607 ) Net unrealized loss on available-for-sale investments — — — — ( 452 ) ( 452 ) Balance - March 31, 2026 244,816,413 $ 245 $ 2,332,129 $ ( 2,053,316 ) $ ( 183 ) $ 278,875 Common Stock Additional Paid-in Capital Accumulated Deficit Accumulated Other Comprehensive Income (Loss) Total Stockholders’ Equity Shares Amount Balance - December 31, 2024 212,210,597 $ 212 $ 2,241,879 $ ( 1,819,823 ) $ ( 89 ) $ 422,179 Issuance of common stock upon exercise of stock options and vesting of RSUs 2,158,522 2 ( 2 ) — — — Issuance of common stock from ATM offering, net of commissions and offering costs of $ 0.2 million 3,842,282 4 9,998 — — 10,002 Stock-based compensation — — 12,175 — — 12,175 Employee stock purchase plan 386,861 1 637 — — 638 Net loss — — — ( 59,733 ) — ( 59,733 ) Net unrealized gain on available-for-sale investments — — — — 132 132 Balance - March 31, 2025 218,598,262 $ 219 $ 2,264,687 $ ( 1,879,556 ) $ 43 $ 385,393 The accompanying notes are an integral part of these unaudited condensed financial statements. 3 Table of Contents ALLOGENE THERAPEUTICS, INC. Condensed Statements of Cash Flows (Unaudited) (In thousands) Three Months Ended March 31, 2026 2025 Cash flows from operating activities: Net loss $ ( 42,607 ) $ ( 59,733 ) Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation 8,270 12,175 Depreciation and amortization 2,869 3,099 Net amortization/accretion on investment securities ( 885 ) ( 1,306 ) Non-cash rent expense 1,069 1,130 Changes in operating assets and liabilities: Deposit placed in escrow 23,479 ( 868 ) Prepaid expenses and other current assets 1,132 ( 623 ) Other long-term assets 84 425 Accounts payable 663 ( 336 ) Accrued and other current liabilities ( 5,101 ) ( 5,223 ) Operating lease liabilities ( 2,202 ) ( 1,833 ) Other long-term liabilities 316 164 Net cash used in operating activities ( 12,913 ) ( 52,929 ) Cash flows from investing activities: Purchases of property and equipment ( 9 ) ( 99 ) Proceeds from maturities of investments 72,115 56,500 Purchase of investments ( 101,694 ) ( 50,225 ) Net cash provided by (used in) investing activities ( 29,588 ) 6,176 Cash flows from financing activities: Proceeds from issuance of common stock from ATM offering, net of commissions and issuance costs 20,668 10,002 Proceeds from CIRM award (Note 5) — 3,350 Proceeds from issuance of common stock upon exercise of stock options 4 — Proceeds from issuance of common stock under the employee stock purchase plan 450 638 Net cash provided by financing activities 21,122 13,990 Net change in cash and cash equivalents and restricted cash ( 21,379 ) ( 32,763 ) Cash and cash equivalents and restricted cash — beginning of period 61,980 85,510 Cash and cash equivalents and restricted cash — end of period $ 40,601 $ 52,747 Non-cash operating activities: Property and equipment purchases in accounts payable and accrued liabilities $ 146 $ — Supplemental disclosure: Cash paid for amounts included in the measurement of lease liabilities $ ( 3,233 ) $ ( 3,227 ) The accompanying notes are an integral part of these unaudited condensed financial statements. 4 Table of Contents ALLOGENE THERAPEUTICS, INC. Notes to Condensed Financial Statements 1. Description of Business Allogene Therapeutics, Inc. (the Company or Allogene) was incorporated on November 30, 2017 in the State of Delaware and is headquartered in South San Francisco, California. Allogene is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. The Company is developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells in patients or eliminate pathogenic autoreactive cells in patients with autoimmune disorders. The Company’s engineered T cells are allogeneic, meaning they are derived from healthy donors for intended use in any patient, rather than from an individual patient for that patient’s use, as in the case of autologous T cells. The Company believes this key difference will enable it to deliver readily available treatments faster, more reliably, at greater scale, and to more patients. Public Offerings In November 2019, the Company entered into a sales agreement with TD Securities (USA) LLC (f/k/a Cowen and Company, LLC) (TD Cowen), as amended on November 2, 2022 and November 2, 2023, under which the Company may from time to time issue and sell shares of its common stock through TD Cowen in at-the-market (ATM) offerings. The aggregate compensation payable to TD Cowen as the Company’s sales agent equals up to 3.0 % of the gross sales price of the shares sold through TD Cowen pursuant to the sales agreement. The specified dollar limit on the amount of common stock that may be sold under the sales agreement was removed pursuant to the November 2, 2023 amendment to the sales agreement. During the three months ended March 31, 2026, the Company sold an aggregate of 12,476,533 shares of common stock in ATM offerings resulting in net proceeds of $ 20.7 million. On April 13, 2026, in connection with the Company’s April 2026 Public Offering as described in Notes 9 and 13, the Company suspended any further ATM offering under the TD Cowen sales agreement until a new prospectus or prospectus supplement is filed with the Securities and Exchange Commission (SEC). Need for Additional Capital The Company has sustained operating losses and expects to continue to generate operating losses for the foreseeable future. The Company’s ultimate success depends on the outcome of its research and development activities as well as the ability to commercialize the Company’s product candidates. The Company had cash, cash equivalents and investments of $ 266.9 million as of March 31, 2026. Since inception through March 31, 2026, the Company has incurred cumulative net losses of $ 2,053.3 million. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan. The Company may raise additional capital through the issuance of equity securities, debt financings, collaborations or other sources to further implement its business plan. If additional financing is not available at adequate levels, the Company may need to reevaluate its operating plan and may be required to delay the development of its product candidates. The Company expects that its cash, cash equivalents and investments as of March 31, 2026, together with the net proceeds from the April 2026 Public Offering as described in Notes 9 and 13, will be sufficient to fund its operations for at least the next 12 months from the date the accompanying unaudited condensed financial statements are filed with the SEC. 2. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the Company’s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included. The condensed balance sheet as of March 31, 2026, the condensed statements of operations and comprehensive loss for the three months ended March 31, 2026 and 2025, the condensed statements of stockholders’ equity as of March 31, 2026 and 2025, the condensed statements of cash flows for the three months ended March 31, 2026 and 2025, and the financial data and other financial information disclosed in the notes to the condensed financial statements are unaudited. The results of 5 Table of Contents operations for the three months ended March 31, 2026 are not necessarily indicative of the results to be expected for the year ending December 31, 2026, or for any other future annual or interim period. These condensed financial statements should be read in conjunction with the Company’s audited financial statements and related notes for the year ended December 31, 2025, included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 12, 2026 (Annual Report). Use of Estimates The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed financial statements include but are not limited to the fair value of common stock, the fair value of stock options, the fair value of investments, income tax uncertainties, the CIRM (as defined below) award liability, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances change. Actual results could differ from those estimates. Significant Accounting Policies There have been no significant changes to the accounting policies during the three months ended March 31, 2026, as compared to the significant accounting policies described in Note 1 of the “Notes to Financial Statements” in the Company’s audited financial statements included in its Annual Report. Recently Adopted Accounting Pronouncements There have been no new accounting pronouncements issued or effective that are expected to have a material impact on the Company’s condensed financial statements. Recent Accounting Pronouncements Not Yet Adopted In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40), which requires new disclosures to disaggregate prescribed natural expenses underlying any income statement caption. ASU 2024-03 is effective for annual periods in fiscal years beginning after December 15, 2026, and interim periods thereafter. Early adoption is permitted. ASU 2024-03 applies on a prospective basis for periods beginning after the effective date. However, retrospective application to any or all prior periods presented is permitted. The Company is currently assessing the impact ASU 2024-03 will have on the financial statements and disclosures. In September 2025, the FASB issued ASU 2025-06, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, which modernizes the accounting for internal-use software costs. ASU 2025-06 removes all references to prescriptive and sequential software development stages throughout Subtopic 350-40. Therefore, an entity is required to start capitalizing software costs when both of the following occur: 1) Management has authorized and committed to funding the software project and 2) It is probable that the project will be completed and the software will be used to perform the function intended. ASU 2025-06 is effective for annual periods beginning after December 15, 2027, with early adoption permitted as of the beginning of an annual period. The Company is currently in the process of evaluating the impact of this pronouncement on the financial statements and disclosures. 3. Fair Value Measurements The Company measures and reports its cash equivalents, restricted cash, and investments at fair value. Money market funds are measured at fair value on a recurring basis using quoted prices and are classified as Level 1. Investments are measured at fair value based on inputs other than quoted prices that are derived from observable market data and are classified as Level 2 inputs, except for investments in U.S. treasury securities which are classified as Level 1. There were no Level 3 assets or liabilities as of March 31, 2026 and as of December 31, 2025. 6 Table of Contents Financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of March 31, 2026 and as of December 31, 2025 are presented in the following tables: March 31, 2026 Level 1 Level 2 Level 3 Fair Value (In thousands) Financial Assets: Money market funds (1) $ 25,055 $ — $ — $ 25,055 Commercial paper — 86,739 — 86,739 Corporate bonds — 69,100 — 69,100 U.S. treasury securities 61,834 — — 61,834 U.S. agency securities — 18,904 — 18,904 Total financial assets $ 86,889 $ 174,743 $ — $ 261,632 December 31, 2025 Level 1 Level 2 Level 3 Fair Value (In thousands) Financial Assets: Money market funds (1) $ 48,576 $ — $ — $ 48,576 Commercial paper — 42,704 — 42,704 Corporate bonds — 53,705 — 53,705 U.S. treasury securities 76,157 — — 76,157 U.S. agency securities — 33,999 — 33,999 Total financial assets $ 124,733 $ 130,408 $ — $ 255,141 (1) Included within cash and cash equivalents on the Company’s condensed balance sheets. 4. Financial Instruments The fair value and amortized cost of cash equivalents and available-for-sale securities by major security type as of March 31, 2026 and as of December 31, 2025 are presented in the following tables: March 31, 2026 Amortized Cost Unrealized Gains Unrealized Losses Fair Value (In thousands) Money market funds $ 25,055 $ — $ — $ 25,055 Commercial paper 86,915 2 ( 178 ) 86,739 Corporate bonds 69,145 10 ( 55 ) 69,100 U.S. treasury securities 61,791 52 ( 9 ) 61,834 U.S. agency securities 18,909 2 ( 7 ) 18,904 Total cash equivalents and investments $ 261,815 $ 66 $ ( 249 ) $ 261,632 Classified as: Cash equivalents $ 25,055 Short-term investments 236,577 Long-term investments — Total cash equivalents and investments $ 261,632 7 Table of Contents December 31, 2025 Amortized Cost Unrealized Gains Unrealized Losses Fair Value (In thousands) Money market funds $ 48,576 $ — $ — $ 48,576 Commercial paper 42,696 18 ( 10 ) 42,704 Corporate bonds 53,636 69 — 53,705 U.S. treasury securities 75,990 167 — 76,157 U.S. agency securities 33,974 25 — 33,999 Total cash equivalents and investments $ 254,872 $ 279 $ ( 10 ) $ 255,141 Classified as: Cash equivalents $ 48,576 Short-term investments 198,522 Long-term investments 8,043 Total cash equivalents and investments $ 255,141 As of March 31, 2026, the remaining contractual maturities of available-for-sale securities were less than 1 year. There were no significant realized losses on available-for-sale securities for the three months ended March 31, 2026 and 2025. As of March 31, 2026, unrealized losses on available-for-sale securities are not attributed to credit risk. The Company believes that it is more likely than not that investments in an unrealized loss position will be held until maturity and all interest and principal will be received. The Company believes that an allowance for credit losses is unnecessary because the unrealized losses on certain of the Company’s available-for-sale securities are due to market factors. As of March 31, 2026 and December 31, 2025, there were no securities in a continuous net unrealized loss position for more than 12 months. To date, the Company has not recorded any impairment charges on available-for-sale securities. The Company has made an accounting policy election not to recognize an allowance for credit losses for accrued interest receivable on available-for-sale securities. As of March 31, 2026 and December 31, 2025, the Company recognized $ 1.3 million and $ 1.5 million, respectively, of accrued interest receivable from available-for-sale securities within prepaid expenses and other current assets on the condensed balance sheets. 5. Balance Sheet Components Property and Equipment, Net Property and Equipment consist of the following: March 31, 2026 December 31, 2025 (In thousands) Leasehold improvements $ 107,537 $ 107,537 Laboratory equipment 28,792 28,748 Computer equipment and purchased software 4,873 4,873 Furniture and fixtures 4,223 4,214 Total 145,425 145,372 Less: accumulated depreciation ( 75,402 ) ( 72,533 ) Total property and equipment, net $ 70,023 $ 72,839 Accrued and Other Current Liabilities On May 12, 2025, the Company’s Board of Directors approved an approximately 28 % reduction in the Company’s employee workforce (Workforce Reduction) in connection with a reduction in manufacturing operations and a reprioritization of resources to focus on the Company’s clinical programs. The Workforce Reduction included one-time severance payments and other employee benefits and resulted in impairment of equipment. During the year ended December 31, 2025, the Company 8 Table of Contents recorded $ 3.1 million, $ 0.3 million, and $ 1.3 million in research and development expense, general and administrative expense, and equipment impairment, respectively, in the statement of operations and comprehensive loss. There were no such costs for the three months ended March 31, 2026 and 2025, respectively. As of March 31, 2026, there were no remaining severance and other employee benefits accruals. California Institute for Regenerative Medicine (CIRM) Award On April 26, 2024, the Company was awarded up to $ 15.0 million from CIRM to support the clinical development of ALLO-316, an AlloCAR T investigational product targeting CD70 in development for the treatment of advanced or metastatic renal cell carcinoma (RCC). Upon treatment of 20 patients, the Company met the primary study objectives of the ALLO-316 Phase 1b study plan supported by CIRM and was able to successfully complete the study plan on time and under budget without further enrollment. As a result, the Company updated the study plan and requested a reduction in its co-funding responsibility and adjustments to the remaining milestone payments to align with the updated research plan. On April 28, 2025, the terms of the award were amended, and the total award amount was adjusted to up to $ 9.2 million. Pursuant to terms of the award, the disbursements are tied to the achievement of specified operational milestones. In addition, the terms of the award and amended award include a co-funding requirement pursuant to which the Company is required to spend up to approximately $ 15.7 million of its own capital to fund the CIRM funded research project. The award was made in accordance with the CIRM Grants Administration Policy for Clinical Stage Projects which may require the award to be repaid by the Company. Under the terms of the CIRM award, the Company is obligated to pay royalties based on a low single digit royalty percentage on net sales of CIRM-funded product candidate. The maximum royalty that the Company may be required to pay to CIRM is equal to nine times the total amount awarded and paid to the Company. After completing the CIRM funded research project and at any time after the award period end date (but no later than the ten-year anniversary of the date of the award), the Company has the right, upon its election, to convert the award into a loan. The terms of conversion into a loan will be determined based on various factors and could result in 80 % to 100 % plus interest at 10 % per annum plus the Secured Overnight Financing Rate of the total award dependent upon the phase of clinical development of the product candidate at the time of the Company’s election to be repaid to CIRM. No income associated with the CIRM award will be recognized until it is confirmed with CIRM that the award does not require repayment. Upon cash receipt, the CIRM award and accrued interest will be recognized as other long-term liabilities on the condensed balance sheets. The Company will not recognize a receivable of future awards until it is approved by CIRM. The Company received $ 9.2 million from CIRM through March 31, 2026 and accounted for the proceeds as a liability within other long-term liabilities on the condensed balance sheets. The Company recorded interest expense of $ 0.3 million and $ 0.2 million for the three months ended March 31, 2026 and 2025, respectively. As of March 31, 2026, $ 1.6 million of accrued interest was included in other long-term liabilities. 6. License and Collaboration Agreements Asset Contribution Agreement with Pfizer In April 2018, the Company entered into an Asset Contribution Agreement (the Pfizer Agreement) with Pfizer pursuant to which the Company acquired certain assets and assumed certain liabilities from Pfizer, including agreements with Cellectis S.A. (Cellectis) and Servier as described below, and other intellectual property for the development and administration of chimeric antigen receptor (CAR) T cells for the treatment of cancer. The Company is required to make payments upon the achievement of certain sales and regulatory milestones and pay royalties on certain net sales pursuant to the Pfizer Agreement as further described in Note 6 to the Annual Report. For the three months ended March 31, 2026 and 2025, no milestones were achieved and no royalty payments were made. Research Collaboration and License Agreement with Cellectis As part of the Pfizer Agreement, Pfizer assigned to the Company a Research Collaboration and License Agreement (the Original Cellectis Agreement) with Cellectis S.A. (Cellectis). On March 8, 2019, the Company entered into a License Agreement (the Cellectis Agreement) with Cellectis and terminated the Original Cellectis Agreement. Pursuant to the Cellectis Agreement, Cellectis granted to the Company an exclusive, worldwide, royalty-bearing license, on a target-by-target basis, with sublicensing rights under certain conditions, under certain of Cellectis’s intellectual property, including its TALEN and electroporation technology, to make, use, sell, import, and otherwise exploit and 9 Table of Contents commercialize CAR T products directed at certain targets, including B-cell maturation antigen (BCMA), CD70, Claudin 18.2, DLL3 and FLT3 (the Allogene Targets), for human oncologic therapeutic, diagnostic, prophylactic and prognostic purposes. The Company is required to make payments upon the achievement of certain development and sales milestones and pay royalties on certain net sales pursuant to the Cellectis Agreement as further described in Note 6 to the Annual Report. In April 2026, the Company received correspondence from Life Technologies Corporation (LTC), a subsidiary of Thermo Fisher Scientific, asserting that Cellectis had sublicensed to the Company or otherwise made available rights under certain patents licensed by LTC to Cellectis relating to TALEN technology, and that LTC had terminated its license agreements with Cellectis. Cellectis separately informed the Company that LTC had purported to terminate certain license agreements with Cellectis and commenced an arbitration against Cellectis and Cellectis Bioresearch before the American Arbitration Association. Cellectis also informed the Company that it disputes the purported termination and the claims asserted by LTC. The Company is not a party to the arbitration and is evaluating the potential impact, if any, on its rights under the Cellectis Agreement and its other rights relating to product candidates that use TALEN technology. For the three months ended March 31, 2026 and 2025, no milestones were achieved and no royalty payments were made. Exclusive License Agreement with Servier As part of the Pfizer Agreement, Pfizer assigned to the Company an Exclusive License Agreement (the Original Servier Agreement), with Les Laboratoires Servier SAS and Institut de Recherches Internationales Servier SAS (collectively, Servier) to develop, manufacture and commercialize certain allogeneic anti-CD19 CAR T cell product candidates, including UCART19, in the United States with the option to obtain the rights over additional anti-CD19 product candidates and for allogeneic CAR T cell product candidates directed against one additional target. In October 2019, the Company agreed to waive its rights to the one additional target. On May 10, 2024, the Company and Servier entered into an Amendment and Settlement Agreement (the Servier Amendment) which restructured the parties’ relationship under the Original Servier Agreement (as amended, the Servier Agreement). The Company’s licensed territory was expanded to include the European Union and the United Kingdom. The Company was also granted an option to further extend its licensed territory to include China and Japan upon the objective showing of sufficient resources to develop licensed products in those countries, which could be met through the Company entering into a strategic partnership covering those countries. Additionally, the Company agreed to waive certain of its rights under the Original Servier Agreement to elect a conversion of its license to the products directed against CD19, including UCART19, ALLO-501 and cemacabtagene ansegedleucel (cema-cel, previously ALLO-501A) (collectively, CD19 Products) to a worldwide license. Under the Servier Agreement, the Company is required to use commercially reasonable efforts to develop, manufacture and commercialize a CD19 Product. Under the Servier Agreement, Servier sublicenses to the Company certain rights which Servier licenses from Cellectis pursuant to a License, Development and Commercialization Agreement by and between Cellectis and Servier, dated February 7, 2014, as amended by Amendment No. 1 to the License, Development and Commercialization Agreement, dated March 4, 2020 (as amended, the Servier-Cellectis Agreement). As amended by the Servier Amendment, all of the Company’s future milestone payments (regulatory and sales) under the Original Servier Agreement were modified to be the same as, and to coincide with, Servier’s milestone payments to Cellectis that are required under the Servier-Cellectis Agreement. The Servier Agreement provides for aggregate potential milestone payments by the Company to Servier of up to € 75.0 million upon successful completion of various regulatory milestones and first commercial sale milestones in the United States, European Union and the United Kingdom for the initial indication of each licensed product, of which € 60.0 million remains for the initial indication for cema-cel, with additional payments of € 55.0 million, due for each subsequent indication, of which € 50.0 million remains for the first subsequent indication for cema-cel, and aggregate potential payments by the Company to Servier of up to € 80.0 million upon achievement of certain net sales milestones for each licensed product. Should Servier’s rights and obligations under the Servier-Cellectis Agreement be assigned to the Company, these milestone payments would terminate, and the Company would assume Servier’s milestone payment obligations to Cellectis. In the absence of any such assignment, Servier will remain responsible for making milestone payments that may be due to Cellectis under the Servier-Cellectis Agreement. The Company previously transferred € 20.0 million into an escrow account in connection with a potential future milestone payment, which is included in the remaining € 60.0 million in milestone payments referenced above for the initial indication for cema-cel. The milestone would have been payable upon the occurrence of certain development, regulatory or adjudicative events. On December 15, 2025, an arbitral tribunal issued a decision providing for a partial termination of the Servier-Cellectis Agreement with respect to UCART19V1 (ALLO-501), which the Company previously abandoned in favor of cema-cel (formerly known as ALLO-501A). As a result, the Company's Servier license covering UCART19V1/ALLO-501 was terminated and Cellectis was required, at the Company's request, to engage in good-faith discussions regarding a direct license. 10 Table of Contents On February 13, 2026, the € 20.0 million balance in escrow was remitted to the Company, resulting in net cash proceeds of $ 23.7 million. The Company is obligated to pay to Servier royalties on annual net sales of any licensed products that are commercialized by the Company that are directed at CD19. Such royalties include tiered royalties on annual net sales in the United States and a flat royalty on annual net sales in territories outside the United States. The United States royalty rates are in a range from the low tens to the mid teen percentages and the ex-U.S. royalty rate is 10 %. Such royalties may be reduced for interchangeable drug entry, expiration of patent rights and amounts paid pursuant to licenses of third-party patents. This royalty obligation begins upon the first commercial sale of such product in a given country and ends after the later of a defined number of years or the expiration of the last to expire licensed patent covering the product in such country. The net effect of the Servier Amendment is that the Company’s royalty rate in the United States for the first half of the first tier of net sales was increased by a low single digit percentage as compared to the Original Servier Agreement. Should Servier’s rights and obligations under the Servier-Cellectis Agreement be assigned to the Company, each tier of royalty rates in the United States to Servier would be reduced by 10 %, the ex-U.S. royalties to Servier would terminate, and the Company would assume Servier’s royalty obligations to Cellectis. In the absence of any such assignment, Servier will remain responsible for making royalty payments that may be due to Cellectis under the Servier-Cellectis Agreement. The Company’s rights under the Servier Agreement with respect to CD19 Products, including cema-cel, depend in part on rights sublicensed by Servier from Cellectis. Accordingly, the purported termination of certain license agreements between LTC and Cellectis described above under “Research Collaboration and License Agreement with Cellectis” could also affect the Company’s rights with respect to CD19 Products if LTC were successful in challenging Cellectis’ rights and if the affected rights are necessary for the development, manufacture or commercialization of such products. The Company is not a party to the arbitration between LTC and Cellectis and is evaluating the potential impact, if any, on its rights under the Servier Agreement. For the three months ended March 31, 2026 and 2025, no milestones were achieved and no royalty payments were made. Research Collaboration and License Agreement with Roche (formerly Notch Therapeutics) On November 1, 2019, the Company entered into a Collaboration and License Agreement (the Notch Agreement) with Notch Therapeutics Inc. (Notch), pursuant to which Notch granted to Allogene an exclusive, worldwide, royalty-bearing, sublicensable license under certain of Notch’s intellectual property to develop, make, use, sell, import, and otherwise commercialize therapeutic gene-edited T cell and/or natural killer (NK) cell products from induced pluripotent stem cells directed at certain CAR targets for initial application in non-Hodgkin lymphoma, acute lymphoblastic leukemia and multiple myeloma. Pursuant to the Notch Agreement, the Company made certain investments in Notch’s capital stock as further described in Note 6 to the Annual Report. On January 25, 2024, the Company entered into an Amended and Restated Collaboration and License Agreement under which the Company has relinquished its exclusive rights to all original CAR targets except one, limited its option right to one additional CAR target and became entitled to a percentage of certain third party upfront and/or milestone payments (up to a stated cap) and a low, single-digit royalty on net sales if Notch out-licenses any released targets. If the option is exercised, the Company will have a minimum funding commitment for the overall development program. Following F. Hoffmann-La Roche AG’s (Roche) acquisition of Notch, in March 2025, Notch was dissolved, and Roche became Notch’s successor in interest under the Company’s agreement. In connection with such acquisition, on March 31, 2025 the Company entered into a Second Amendment to Amended and Restated Collaboration and License Agreement (Second Amended Notch Agreement) with Notch under which the definitions of certain terms were clarified, certain time periods for completing the transfer of certain technology were extended, and the scope of Allogene’s exclusive rights were clarified. Notch dissolved on September 2, 2025 and final proceeds were distributed to the Company. The Company’s total equity investment in Notch as of March 31, 2026 and December 31, 2025 was zero . For the three months ended March 31, 2026 and 2025, no milestones were achieved. Strategic Alliance with The University of Texas MD Anderson Cancer Center On October 6, 2020, the Company entered into a strategic five-year collaboration agreement with The University of Texas MD Anderson Cancer Center (MD Anderson) for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. In August 2025, the Company extended the term of the agreement for an additional year. The Company and MD Anderson are collaborating on the design and conduct of preclinical and clinical studies with oversight from a joint steering committee. 11 Table of Contents Under the terms of the agreement, the Company has committed up to $ 15.0 million of funding for the duration of the agreement, of which $ 6.0 million remains. Payment of this funding is contingent on mutual agreement to study orders in order for any study to be included under the alliance. The Company is committed to make further payments to MD Anderson each year upon the anniversary of the agreement effective date through the duration of the agreement term, however, if MD Anderson has sufficient funds to continue the agreed-upon research projects, the Company may defer the additional payment to a later date. These costs are expensed to research and development as MD Anderson renders the services under the strategic alliance. Collaboration costs recorded as research and development expenses were $ 0.1 million and $ 0.4 million for the three months ended March 31, 2026 and 2025, respectively. Investment in and License Agreement with Overland Therapeutics, Inc. Allogene Overland Biopharm (CY) Limited (Allogene Overland), later renamed Overland Therapeutics Inc. (Overland Therapeutics), was initially established as a joint venture by the Company and Overland Pharmaceuticals (CY) Inc. (Overland) pursuant to a Share Purchase Agreement (Share Purchase Agreement), dated December 14, 2020. Concurrently, on December 14, 2020, the Company entered into a License Agreement (License Agreement) with Allogene Overland for the purpose of developing, manufacturing and commercializing certain allogeneic CAR T cell therapies for patients in greater China, Taiwan, South Korea and Singapore (the JV Territory). Pursuant to the Share Purchase Agreement, the Company and Overland acquired Seed Preferred Shares of Allogene Overland representing 49 % and 51 %, respectively, of Allogene Overland’s outstanding stock. On May 24, 2024, the Company, Overland, and Allogene Overland entered into a Share Exchange Agreement (Share Exchange Agreement) pursuant to which Overland’s cell therapy business merged into Allogene Overland (the Organizational Restructuring). Under the Share Exchange Agreement, Allogene Overland acquired from Overland a 100 % equity interest in Overland Pharmaceuticals (U.S.) Inc. (Overland U.S.). Overland U.S. includes certain research and development, clinical, and general and administrative staff, as well as select cell therapy assets, including its lead program, OL-101, an autologous GPRC5D-BCMA bispecific dual targeting CAR T for refractory multiple myeloma. Upon completion of the closing of the share exchange, Overland U.S. became a wholly owned subsidiary of Allogene Overland, Overland’s ownership increased to 82 % and the Company’s ownership decreased to 18 %. Under a separate agreement between Overland and HH BioPharma Holdings Ltd. (HBP) executed on May 24, 2024, Overland distributed all Series Seed Preferred Shares of Allogene Overland held by Overland to HBP and HBP has assumed all rights and obligations attached to such shares and all rights and obligations of Overland under the Share Exchange Agreement. In connection with the Organizational Restructuring, on May 24, 2024, the Company and Allogene Overland PRC, entered into a First Amendment to the License Agreement (the License Amendment) to amend and supplement certain provisions of the License Agreement. Under the License Amendment, the Company continues to grant Allogene Overland PRC an exclusive license to develop, manufacture, and commercialize the Licensed Products in the JV Territory, with the Company retaining exclusive rights to the Licensed Products outside the JV Territory, and the royalty obligations to the Company were amended to a flat mid single-digit royalty on net sales in the JV Territory that are no longer subject to reductions. The License Amendment also provides the Company with additional rights to terminate the License Agreement in its entirety or with respect to the relevant Overland Licensed Products if Allogene Overland PRC fails to initiate manufacturing technology transfer with respect to an Overland Licensed Product as agreed in the License Amendment, or if HBP commits a funding default or a material breach of its representations, warranties, or covenants under the Share Exchange Agreement. The License Amendment also provides that the License Agreement will terminate automatically if the Company’s ownership in Allogene Overland falls below 7.5 % (other than due to the Company’s sale of the shares of Allogene Overland), unless at that time Allogene Overland PRC and the Company have mutually agreed on the manufacturing technology transfer plan for the Overland Licensed Products and Allogene Overland PRC elects to continue the license for such Overland Licensed Products with increased milestones and royalties. Under the License Amendment terms such increased milestones and royalties consist of up to $ 115.0 million in milestone payments for each Overland Licensed Product and tiered mid single-digit to low double-digit royalties on net sales in the JV Territory. As part of the Organizational Restructuring, Allogene Overland was renamed Overland Therapeutics Inc. (Overland Therapeutics). The Company determined that Overland Therapeutics is a variable interest entity as of March 31, 2026 and December 31, 2025. The Company does not have the power to direct the activities which most significantly affect Overland Therapeutics’ economic performance. Accordingly, the Company did not consolidate Overland Therapeutics because the Company determined that it was not the primary beneficiary. After the Organizational Restructuring, the Company has 20 % voting rights of Overland Therapeutics’ board of directors. The Company concluded that it has significant influence over 12 Table of Contents Overland Therapeutics and continued to account for its investment in Overland Therapeutics as an equity method investment. The Company’s total equity investment in Overland Therapeutics as of March 31, 2026 and December 31, 2025 was zero . Collaboration revenue was zero for the three months ended March 31, 2026 and 2025. As of March 31, 2026 and December 31, 2025, $ 4.6 million of deferred revenue was recorded in other long-term liabilities. On May 12, 2026, the Company entered into a termination agreement with Overland Therapeutics (SH) Co. Ltd. and Overland Therapeutics Inc., pursuant to which the License Agreement was terminated in its entirety. The parties also provided mutual releases of claims, and no termination payments were made in connection with the termination. In connection with the termination and related transactions, the Company surrendered a portion of its equity interests in Overland Therapeutics, resulting in a reduction of its ownership interest to approximately 3 % on an as-converted and fully diluted basis. The Company is assessing the impact of these transactions on its operations and financial statements. Collaboration and License Agreement with Antion On January 5, 2022, the Company entered into an exclusive collaboration and global license agreement (Antion Collaboration and License Agreement) with Antion Biosciences SA (Antion) for Antion’s miRNA technology (miCAR), to advance multiplex gene silencing as an additional tool to develop next generation allogeneic CAR T products. In July 2023, the Company and Antion entered into an amendment to the Antion Collaboration and License Agreement. Under the terms of this amendment, Antion’s exclusivity obligation relating to the collaboration was terminated; however, Antion agreed to certain restrictions on its ability to pursue products directed against specific targets. Also, in lieu of the Company’s prior obligation to make a $ 3.0 million investment in Antion following the completion of certain milestones, the Company agreed to make a $ 2.0 million investment in Antion’s preferred stock and acquired warrants to purchase an additional $ 3.0 million of Antion’s preferred stock. The Company is required to make payments upon the achievement of certain development and regulatory milestones and pay royalties on certain sales pursuant to the Antion Collaboration and License Agreement as further described in Note 6 to the Annual Report. As of March 31, 2026 and December 31, 2025, the Company’s total equity investment in Antion was zero . Strategic Collaboration Agreement with Foresight Diagnostics On January 3, 2024, the Company entered into a Strategic Collaboration Agreement with Foresight Diagnostics, Inc. (Foresight Diagnostics) (the Foresight Agreement). Foresight Diagnostics was acquired by Natera, Inc. (Natera) in December 2025 and continues to operate as a standalone subsidiary. Pursuant to the Foresight Agreement, the parties have agreed to collaborate on a non-exclusive basis in the development of Foresight Diagnostics’ minimal residual disease (MRD) assay based on their PhasED-Seq Circulating Tumor DNA Platform as an in vitro diagnostic to identify the MRD+ patient population to be enrolled in the Company’s planned ALPHA3 trial of cema-cel, for treatment of large B-cell lymphoma (LBCL). Under the Foresight Agreement, the Company has agreed to use its commercially reasonable efforts to obtain regulatory approval of cema-cel, and Foresight Diagnostics has agreed to use its commercially reasonable efforts to obtain regulatory approval of its MRD assay for use as an in vitro diagnostic with cema-cel. Under the Foresight Agreement, the Company has agreed to fund approximately $ 26.2 million in MRD assay development costs, milestone payments for regulatory submissions and assay utilization to process clinical samples. On February 19, 2025, the Company entered into an Amended and Restated Strategic Collaboration Agreement with Foresight Diagnostics which expands its collaboration to include the development of Foresight Diagnostics’ MRD assay for use with cema-cel as part of a possible EU and/or UK clinical development program, and as part of an expansion of ALPHA3 to Canadian and Australian clinical trial sites in support of the U.S. clinical development program. In total, the Company agreed to fund approximately $ 37.3 million in MRD assay development costs, milestone payments for U.S., and certain international regulatory submissions and assay utilization costs to process clinical samples, all in addition to the financial commitments under the Foresight Agreement. Clinical trial milestones recorded as research and development expenses were $ 2.5 million and $ 1.3 million for the three months ended March 31, 2026 and 2025, respectively. As of March 31, 2026 and December 31, 2025, $ 2.5 million and $ 1.4 million in research and development expenses, respectively, were recorded in accrued and other liabilities. 7. Commitments and Contingencies Leases In August 2018, the Company entered into an operating lease agreement (HQ Lease) for office and laboratory space which consists of approximately 68,000 square feet located in South San Francisco, California. In December 2021, the 13 Table of Contents Company amended its lease agreement to lease an additional 47,566 square feet of office and laboratory space in South San Francisco, California, as part of the same building as the Company’s current headquarters. The lease term commenced in April 2022. The rent payments for the expansion premises began in August 2022. The lease term for both the existing and expansion premises will expire on March 31, 2032 with an option to extend the term for eight years which is not reasonably assured of exercise. In October 2018, the Company entered into an operating lease agreement for office and laboratory space which consists of 14,943 square feet located in South San Francisco, California. The lease term will expire March 31, 2032 with an option to extend the term for eight years which is not reasonably assured of exercise. In February 2019, the Company entered into a lease agreement for approximately 118,000 square feet of space to develop a cell therapy manufacturing facility in Newark, California. The lease term will expire on July 31, 2036 with two ten-year options to extend the lease, both of which are not reasonably assured of exercise. In February 2023, the Company entered into a sublease with Bellco Capital Advisors Inc. (Bellco) for 2,218 square feet of office space in Los Angeles, California, which was subsequently reduced to 1,944 square feet in February 2026. The sublease term is 115 months, subject to certain early termination rights. The sublease commenced on January 1, 2024. The Company maintains letters of credit for the benefit of landlords which is disclosed as restricted cash in the condensed balance sheets. Restricted cash related to letters of credit due to landlords was $ 6.0 million as of March 31, 2026 and December 31, 2025. The balance sheet classification of the Company’s lease liabilities was as follows (in thousands): March 31, 2026 December 31, 2025 Operating lease liabilities Current portion included in accrued and other current liabilities $ 8,418 $ 8,208 Lease liability, noncurrent 72,633 75,045 Total operating lease liabilities $ 81,051 $ 83,253 The components of lease costs for operating leases, which were recognized in operating expenses, were as follows (in thousands): Three Months Ended March 31, 2026 2025 Operating lease cost $ 2,344 $ 2,525 Variable lease cost 601 556 Total lease costs $ 2,945 $ 3,081 The undiscounted future non-cancellable lease payments under the Company’s operating leases as of March 31, 2026 were as follows: Year ending December 31: (In thousands) 2026 (remaining 9 months) $ 9,897 2027 13,574 2028 14,037 2029 15,437 2030 16,148 2031 and thereafter 33,597 Total undiscounted lease payments 102,690 Less: Present value adjustment ( 21,639 ) Total $ 81,051 Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company uses its estimated incremental borrowing rate. The weighted average discount rate used to determine the operating lease liability was 6.50 %. As of March 31, 2026, the weighted average remaining lease term for the Company’s operating leases is 6.94 years. 14 Table of Contents In December 2024 and January 2025, the Company entered into non-cancelable agreements under which it subleased approximately 46,011 square feet of its HQ Lease to two unaffiliated companies. In July 2025, the Company entered into a non-cancelable agreement under which it subleased one of its leased buildings in South San Francisco to one unaffiliated company. During the three months ended March 31, 2026 and 2025, the Company recognized $ 0.8 million and $ 0.3 million, respectively, in sublease income under the interest and other income, net caption within the condensed statements of operations. Other Commitments In July 2020, the Company entered into a Solar Power Purchase and Energy Services Agreement for the installation and operation of a solar photovoltaic generating system and battery energy storage system at the Company’s cell therapy manufacturing facility in Newark, California. The agreement has a term of 20 years and commenced in September 2022. The Company is obligated to pay for electricity generated from the system at an agreed rate for the duration of the agreement term. Termination of the agreement by the Company will result in a termination payment due of approximately $ 4.3 million. In connection with the agreement, the Company maintains a letter of credit for the benefit of the service provider in the amount of $ 4.3 million which is recorded as restricted cash in the condensed balance sheets as of March 31, 2026 and December 31, 2025. The Company has entered into certain license agreements for intellectual property which is used as part of its development and manufacturing processes. Each of these respective agreements are generally cancellable by the Company. These agreements require payment of annual license fees and may include conditional milestone payments for achievement of specific research, clinical and commercial events, and royalty payments. The timing and likelihood of any significant conditional milestone payments or royalty payments becoming due was not probable as of March 31, 2026. Legal Proceedings In the ordinary course of business, the Company or its business partners are from time to time subject to legal claims and regulatory actions that could have a material adverse effect on its business or financial position. The Company assesses its potential liability in such situations by analyzing the possible outcomes of various litigation, regulatory, and settlement strategies. If the Company determines that a material loss is probable and its amount can be reasonably estimated, it will accrue an amount equal to the estimated loss. As of March 31, 2026, the Company did not accrue any estimated losses related to its ongoing legal proceedings. 8. Stock-Based Compensation As of March 31, 2026, there were 8,964,856 shares reserved by the Company under the 2018 Equity Incentive Plan (the 2018 Plan) for the future issuance of equity awards. Stock Option Activity The following summarizes option activity under the 2018 Plan: Outstanding Options Number of Options Weighted- Average Exercise Price Weighted- Average Remaining Contract Term Aggregate Intrinsic Value (in years) (in thousands) Balance as of December 31, 2025 31,138,077 $ 6.31 7.17 $ 97 Options granted 6,995,020 1.87 Options exercised ( 2,438 ) $ 1.94 Options forfeited ( 214,612 ) 4.81 Balance as of March 31, 2026 37,916,047 5.50 7.48 $ 9,302 Exercisable as of March 31, 2026 22,823,105 7.81 6.32 $ 1,282 Vested and expected to vest as of March 31, 2026 37,916,047 $ 5.50 7.48 $ 9,302 Restricted Stock Unit Activity 15 Table of Contents The following summarizes restricted stock unit activity under the 2018 Plan: Outstanding Restricted Stock Units Restricted Stock Units Weighted- Average Grant Date Fair Value per Share Weighted Average Remaining Vesting Life Aggregate Intrinsic Value (in years) (in thousands) Balance as of December 31, 2025 16,528,226 $ 2.99 2.39 $ 22,644 Granted 3,854,459 1.87 Released ( 2,482,047 ) 3.69 Forfeited ( 1,941,228 ) 2.59 Balance as of March 31, 2026 15,959,410 2.66 2.81 $ 38,941 Expected to vest as of March 31, 2026 15,959,410 $ 2.66 2.81 $ 38,941 Vested and unreleased as of March 31, 2026 238,500 $ 1.29 $ 582 As of March 31, 2026, the Company had 4,689,631 outstanding performance-based restricted stock units. No performance-based restricted stock units were granted during the three months ended March 31, 2026. These awards are subject to the holders’ continuous service to the Company through each applicable vesting event. Through March 31, 2026, the Company believes that the achievement of the requisite performance conditions for these awards are not probable. As a result, no compensation expense has been recognized related to the performance-based restricted stock units in the three months ended March 31, 2026 and 2025. As of March 31, 2026, the Company had zero outstanding restricted stock units with a market condition to certain executive officers and other employees pursuant to the 2018 Plan. Stock-based compensation expense recognized related to the restricted stock units with a market condition was zero and less than $ 0.1 million for the three months ended March 31, 2026 and 2025, respectively. Stock-based compensation expense For the three months ended March 31, 2026 and 2025, the following table presents stock-based compensation expense related to stock options, restricted stock units and employee stock purchase plans that was recorded as research and development and general and administrative expense in its condensed statements of operations and comprehensive loss: Three Months Ended March 31, 2026 2025 Research and development $ 2,696 $ 5,040 General and administrative 5,574 7,135 Total stock-based compensation $ 8,270 $ 12,175 9. Related Party Transactions Collaboration Revenue and Equity Method Investment In December 2020, the Company entered into the License Agreement with Overland Therapeutics, a corporate joint venture entity and related party (see Note 6). The License Agreement was subsequently assigned to a wholly-owned subsidiary of Allogene Overland, Allogene Overland HK. On April 1, 2022, Allogene Overland HK assigned the License Agreement to Allogene Overland Biopharm (PRC) Co., Limited. On May 24, 2024, the License Agreement was amended. On May 12, 2026, the License Agreement was terminated. Sublease Agreement In December 2018, the Company entered into a sublease with Bellco Capital LLC (Bellco) for 1,293 square feet of office space in Los Angeles, California for a three year term. On April 1, 2020, Bellco assumed all rights, title, interests and 16 Table of Contents obligations under the sublease from Bellco. In November 2021, the sublease was extended to June 30, 2025. The sublease was amended, effective in July 2022, to move to a nearby location, with office space of 737 square feet. In 2023, the Company exercised its early termination right under the sublease agreement and the sublease was terminated effective December 31, 2023. In February 2023, the Company entered into a new sublease agreement with Bellco for 2,218 square feet of office space in Los Angeles, California, which was subsequently reduced to 1,944 square feet in February 2026. The Company’s executive chairman, Arie Belldegrun, M.D., is a trustee of the Belldegrun Family Trust, which controls Bellco. The sublease term is 115 months, subject to certain early termination rights. The sublease commenced on January 1, 2024. The total right of use asset and associated lease liability recorded related to this related party lease were $ 2.0 million and $ 2.0 million, respectively, as of March 31, 2026. The Company paid approximately $ 0.2 million towards its share of the security deposit. Rent expense related to this sublease were $ 0.1 million and $ 0.1 million for the three months ended March 31, 2026 and 2025, respectively. Consulting Agreements In August 2018, the Company entered into a consulting agreement with Bellco. Pursuant to the consulting agreement, Bellco provides certain services for the Company, which are performed by Dr. Belldegrun, the Company’s executive chair, and inc lude without limitation, providing advice and analysis with respect to the Company’s business, business strategy and potential opportunities in the field of allogeneic CAR T cell therapy and any other aspect of the CAR T cell therapy business as the Company may agree. In consideration for these services, the Company paid Bellco $ 40,217 per month in arrears commencing January 2022. Effective January 2026, the monthly consulting service fee was increased by 2 % to $ 41,021 per month. The Company may also, at its discretion, pay Bellco an annual performance award in an amount up to 60 % of the aggregate compensation payable to Bellco in a calendar year. The Company also reimburses Bellco for out of pocket expenses incurred in performing the services. The costs incurred for services provided, bonus, and out-of-pocket expenses incurred under this consulting agreement were $ 0.2 million and $ 0.2 million for the three months ended March 31, 2026 and 2025, respectively. Co-Manager Agreement On April 14, 2026, the Company entered into an underwriting agreement (Underwriting Agreement) with Goldman Sachs & Co. LLC, Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein (Underwriters), relating to the issuance and sale in a public offering of shares of the Company’s common stock (April 2026 Public Offering). On April 16, 2026, the Company sold 100,200,000 shares to the Underwriters. The price to the public in the offering was $ 2.00 per share. The underwriting discount was $ 0.12 per share. TPG Capital BD, LLC served as an Underwriter for the offering and purchased an aggregate of 3,807,600 shares from the Company at a price of $ 1.88 per share, resulting in an aggregate underwriting discount to TPG Capital BD, LLC of approximately $ 0.5 million. Todd Sisitsky, a member of the Company’s Board of Directors, has served as President and on the Board of Directors of TPG Inc., an affiliate of TPG Capital BD, LLC, since TPG Inc.’s inception. 10. Income Taxes The Company has a history of losses and expects to record a loss in 2026. The Company continues to maintain a full valuation allowance against its net deferred tax assets. 11. Net Loss Per Share The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the period presented due to their anti-dilutive effect: March 31, 2026 2025 Stock options to purchase common stock 37,916,047 31,532,800 Restricted stock units outstanding (Excluding vested but unreleased shares, which are included in weighted-average common shares outstanding) 15,720,910 18,079,422 Expected shares to be purchased under Employee Stock Purchase Plan 1,409,334 1,809,262 Total 55,046,291 51,421,484 17 Table of Contents 12. Segment Reporting The Company has one reportable segment related to developing and commercializing genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. The segment derives its current revenues from research and development collaborations. The CEO, as the chief operating decision maker, manages and allocates resources for the Company’s operations at a consolidated company basis by assessing how to best deploy available resources across functions and research and development projects. The CEO uses consolidated, single-segment financial information for purposes of evaluating performance, planning and forecasting future period financial results, and allocating resources. The table below is the summary of the segment profit or loss information, including the significant segment expenses (in thousands): Three Months Ended March 31, 2026 2025 Significant operating expenses: Cema-cel $ 7,669 $ 6,222 All other development costs 1,999 10,390 Payroll 14,444 19,601 Facilities & IT-related spend 6,418 7,319 Supporting external spend 4,372 5,846 Other operating expenses 11,190 15,813 Total operating expenses 46,092 65,191 Other income (expenses), net 3,485 5,458 Net loss ( 42,607 ) ( 59,733 ) Cema-cel includes external development and clinical trial costs related to ALPHA3, ALPHA2, CLL, and ALLO-501 programs. All other development costs include external development and clinical trial costs related to ALLO-329, ALLO-316, ALLO-647, BCMA, and other programs. Supporting external spend includes professional services, research and development lab supplies and other supporting activities related to the research and development and other business operations. Other operating expenses are primarily related to non-cash expenses such as stock-based compensation, impairment, and depreciation and amortization. The measure of segment assets is reported on the balance sheets as total assets. Primarily, all revenue generated and all long-lived assets are maintained in the United States. 13. Subsequent Events Equity Financing On April 16, 2026, the Company closed the April 2026 Public Offering in which it sold 100,200,000 shares of its common stock at a public offering price of $ 2.00 per share, including 12,700,000 additional shares sold pursuant to the Underwriters’ partial exercise of their option to purchase additional shares. The aggregate gross proceeds were $ 200.4 million and the aggregate net proceeds were approximately $ 187.9 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. Overland License Termination and Equity Restructuring Subsequent to March 31, 2026, the Company entered into a termination agreement with Overland Therapeutics (SH) Co. Ltd. and Overland Therapeutics, Inc., pursuant to which the License Agreement, as defined in Note 6, was terminated in its entirety. Refer to Note 6 for disclosure under the heading “Investment in and License Agreement with Overland Therapeutics, Inc.” 18 Table of Contents